SCHEMBL1672441

SCHEMBL1672441

O=C(O)OB(O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ORAI1 Q96D31 3/20 0.46
ORAI2 Q96SN7 3/20 0.46
ORAI3 Q9BRQ5 3/20 0.46
TRPV6 Q9H1D0 3/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
ENPP2 Q13822 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
PCSK9 Q8NBP7 1/20 0.46
CES2 O00748 3/20 0.36
CES1 P23141 3/20 0.36
AKR1B1 P15121 1/20 0.36
F2 P00734 1/20 0.36
LMNA P02545 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
MGLL Q99685 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27008267 0.94 TRPV6 (0.41) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL28664851 0.84 TRPV6 (0.44) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL384014 0.82 ORAI1 (0.42) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL20916961 0.82 LMNA (0.54) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL56273 0.82 ORAI1 (0.42) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL651370 0.82 ORAI1 (0.42) ORAI1ORAI2ORAI3TRPV6CA4
SCHEMBL14645353 0.81 CA1 (0.55) CA7ENPP2CA14CES2CES1
SCHEMBL3470948 0.80 TSHR (0.50) CA4CA6CA5ACA7CA14
SCHEMBL2352991 0.80 CA2 (0.48) ORAI1ORAI2ORAI3TRPV6CES2
SCHEMBL3793010 0.80 KDM4E (0.35) CA6CA14F2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3995586-B1 GLYCOSYLATED PROTEIN ASSAY REAGENT CONTAINING PROTEASE STABILIZER INCREASING REDOX POTENTIAL OF FERROCYANIDE, METHOD FOR ASSAYING GLYCOSYLATED PROTEIN, METHOD FOR PRESERVING GLYCOSYLATED PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING GLYCOSYLATED PROTEIN ASSAY REAGENT NAGASE DIAGNOSTICS CO LTD (JP) 2025-11-05 EP claimed
EP-3761030-B1 METHOD FOR STABILIZING PROTEIN CONTAINED IN SAMPLE AND SOLUTION FOR STABILIZING PROTEIN CONTAINED IN SAMPLE EIKEN CHEMICAL (JP) 2025-04-30 EP claimed
CN-119552819-A Exosome enrichment method based on boric acid modified capture material 河北大学 2025-03-04 CN claimed
US-12215140-B2 Method of stabilizing protein contained in specimen and solution for stabilizing protein contained in specimen EIKEN KAGAKU KABUSHIKI KAISHA (JP) 2025-02-04 US claimed
US-12188898-B2 Non-enzymatic electrochemical sensor for measuring analytes TERUMO KABUSHIKI KAISHA (JP) 2025-01-07 US claimed
CN-119033953-A Anticancer nano co-carried medicine compound, its preparing method and use 广东医科大学 2024-11-29 CN claimed
CN-118515880-B Phenylboronic acid cross-linking agent and preparation method and application thereof 四川大学 2024-11-26 CN claimed
CN-114805856-B Injectable pH/ROS dual-response hydrogel and preparation method and application thereof 天津大学 2024-11-22 CN claimed
CN-111788484-B Method for stabilizing protein contained in sample, solution for stabilizing protein contained in sample 荣研化学株式会社 2024-11-19 CN claimed
CN-118976121-A Preparation and application methods of viroid cation-like ruthenium-based nanoparticle 山东第一医科大学附属眼科医院(山东省眼科医院) 2024-11-19 CN claimed
EP-2155706-A2 REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY Actavis Group PTC EHF (IS) 2010-02-24 EP claimed
US-7598486-B2 Sample plate for glycoprotein analysis by MALDI mass spectrometry and preparation method of the same Kim, Yangsun (US) 2009-10-06 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2009004485-A2 REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY ACTAVIS GROUP PTC EHF (IS) 2009-01-08 WO claimed
US-20080116367-A1 SAMPLE PLATE FOR GLYCOPROTEIN ANALYSIS BY MALDI MASS SPECTROMETRY AND PREPARATION METHOD OF THE SAME Kim, Yangsun (US) 2008-05-22 US claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
EP-1294404-A2 PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE CORIXA CORPORATION (US) 2003-03-26 EP claimed
WO-2001095943-A2 PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE MEDAREX, INC. (US) 2001-12-20 WO claimed
EP-1107982-A1 REVERSIBLE BORONATE COMPLEXES OF 1,2-$i(CIS)-DIOL CYCLIC-PEPTIDES Eli Lilly & Company (US) 2001-06-20 EP claimed
WO-2000012540-A1 REVERSIBLE BORONATE COMPLEXES OF 1,2-CIS-DIOL CYCLIC-PEPTIDES ELI LILLY AND COMPANY (US) 2000-03-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12188898-B2 Non-enzymatic electrochemical sensor for measuring analytes SPR, SRR, BLVRB ORAI1 2446/4885ORAI2 2680/4885ORAI3 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.